Insight

Galip Can Uyar: Neoadjuvant FOLFOXIRI in High-Risk Locally Advanced Colon Cancer

Galip Can Uyar/LinkedIn

Aug 22, 2025, 13:49

Galip Can Uyar: Neoadjuvant FOLFOXIRI in High-Risk Locally Advanced Colon Cancer

Galip Can Uyar, Medical Doctor at Etlik City Hospital, shared on X about a recent paper by Y.-W. Zhou et al. published on ESMO Open:

“New in ESMO Open (2025):

Neoadjuvant FOLFOXIRI in high-risk locally advanced colon cancer (phase II)

72 patients (T4/N2, median age 53)

Outcomes after 4 cycles:

86.9% TRG 0–2
100% R0 resection
17.2% 2-yr recurrence
51.4% grade 3–4 AEs (hematologic)
1 treatment-related death

Why it matters:

Beyond FOxTROT: in a cohort dominated by T4/N2, triplet chemo achieved striking downstaging and resection rates.

Caveats:

Single-arm, non-randomized design → not confirmatory
Relatively young cohort (median 53) may overestimate tolerability
dMMR subgroup not aligned with current immunotherapy standards

Takeaway:

FOLFOXIRI shows promise for high-risk colon cancer, but phase III trials are needed.”

Title: Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial

Authors: Y.-W. Zhou, G.-X. Wei, X.-R. Chen, P. Cao, M.-T. Wei, C. Fang, X.-B. Deng, L. Li, C. Wang, Y. Shu, Z.-Q. Wang, Y.-Y. Yu, W.-J. Meng, M. Qiu

Read the full article.

FOLFOXIRI

More posts featuring Galip Can Uyar.

C. Fang C. Wang cancer Colon cancer ESMO Open FOLFOXIRI G.-X. Wei Galip Can Uyar L. Li M. Qiu M.-T. Wei OncoDaily Oncology P. Cao W.-J. Meng X.-B. Deng X.-R. Chen Y. Shu Y.-W. Zhou Y.-Y. Yu Z.-Q. Wang

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer